Progesterone and 1,25-Dihydroxyvitamin D3 Inhibit Endometrial Cancer Cell Growth by Upregulating Semaphorin 3B and Semaphorin 3F
Open Access
- 15 November 2011
- journal article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Research
- Vol. 9 (11), 1479-1492
- https://doi.org/10.1158/1541-7786.mcr-11-0213
Abstract
Class 3 semaphorins (SEMA), SEMA3B and SEMA3F, are secreted proteins that regulate angiogenesis, tumor growth, and metastasis by binding to their transmembrane receptor complex consisting of plexins and neuropilins (NP). Expression of SEMAs and their receptors was assessed in tissue microarrays by immunohistochemistry. SEMA3B, SEMA3F, and plexin A3 were expressed strongly in normal endometrial tissues, whereas grade-dependent decreases were found in endometrial carcinomas. No change was observed in the expression of plexin A1, NP1, and NP2 in normal versus endometrial cancer tissues. Endometrial cancer cells showed decreased expression of SEMA3B, SEMA3F, and plexin A3 compared with their normal counterparts. Treatment of cancer cells with progesterone (P4) and 1,25-dihydroxyvitamin D3 [1,25(OH)2D3] for a period of 72 hours induced a significant upregulation of SEMA3B and SEMA3F as well as inhibited growth of cancer cells by increasing caspase-3 activity. Cotreatment of cell lines with P4 or 1,25(OH)2D3 and their respective antagonists confirmed the specificity of their actions. Transfection of siRNA-targeting SEMA3B and SEMA3F in endometrial cancer cells attenuated P4 or 1,25(OH)2D3-induced growth inhibition. Restoration of SEMA3B or SEMA3F expression in cancer cells caused growth inhibition, reduced soft agar colony formation, and cell invasiveness by inhibiting expression of matrix metalloproteinase-2 (MMP-2), MMP-9, integrin αvβ3, and proangiogenic genes and by upregulating antiangiogenic genes. Thus, we have identified two new P4 and 1,25(OH)2D3-regulated antitumor genes for endometrial cancer. These results suggest that the loss of SEMAs contribute to the malignant phenotype of endometrial cancer cells and that reexpression of SEMAs by ectopic expression or with anticancer agents P4 or 1,25(OH)2D3 can be a promising therapeutic treatment against endometrial cancer. Mol Cancer Res; 9(11); 1479–92. ©2011 AACR.Keywords
This publication has 41 references indexed in Scilit:
- Endometrial Carcinoma: A Review of Chemotherapy, Drug Resistance, and the Search for New AgentsThe Oncologist, 2010
- Dietary Vitamin D Exposure Prevents Obesity-Induced Increase in Endometrial Cancer inPten+/−MiceCancer Prevention Research, 2010
- Hormonal Regulation and Distinct Functions of Semaphorin-3B and Semaphorin-3F in Ovarian CancerMolecular Cancer Therapeutics, 2010
- Successful Inhibition of Tumor Development by Specific Class-3 Semaphorins Is Associated with Expression of Appropriate Semaphorin Receptors by Tumor CellsPLOS ONE, 2008
- Semaphorin 3B Is a 1,25-Dihydroxyvitamin D3-Induced Gene in Osteoblasts that Promotes Osteoclastogenesis and Induces Osteopenia in MiceMolecular Endocrinology, 2008
- The tumor suppressor semaphorin 3B triggers a prometastatic program mediated by interleukin 8 and the tumor microenvironmentThe Journal of Experimental Medicine, 2008
- Semaphorin SEMA3F Affects Multiple Signaling Pathways in Lung Cancer CellsCancer Research, 2007
- Oral contraceptive use and cancer. Findings in a large cohort study, 1968–2004British Journal of Cancer, 2006
- Semaphorins in cancerFrontiers in Bioscience-Landmark, 2005
- Hormonal content of combined oral contraceptives in relation to the reduced risk of endometrial carcinomaInternational Journal of Cancer, 1991